CRL Charles River Laboratories

pharma · 2026-10-16

N/A

too hard · 37

Owner-earnings value—

Price$306.24

Margin of safety —

Quality gate · 37/100

Returns on capital 0.2/30

Consistency 11.7/22

Margins / pricing power 9.5/16

Balance sheet 0/16

Cash conversion 10/10

Capital allocation 5.5/6

⚠ sub-hurdle returns (median roic 6% < 9%) · over-levered (net debt/EBITDA 10.7x > 4x)

Median ROIC6.1%

Gross margin32.7%

Net debt / EBITDA10.7x

FCF conversion203%

Share count / yr-1.1%

Profitable years3/4

Moat & management

Owner-earnings inputs

Owner earnings (TTM)	-152.12M
Owner-earnings yield	-1.0%
Free-cash-flow yield	2.5%
Growth used (normalized)	—
Terminal growth	—
Discount rate (hurdle)	—

⚠ maintenance capex ≈ min(capex, D&A), capped at FCF · non-positive owner earnings — cannot value as a going wonderful business

Date	Quality	Price	Value	MoS	Rating
2026-10-16	37	$306.24	—	—	N/A
2026-09-14	37	$278.26	—	—	N/A
2026-08-12	37	$282.00	—	—	N/A
2026-07-10	37	$233.60	—	—	N/A
2026-07-02	37	$229.09	—	—	N/A
2026-06-25	37	$202.10	—	—	N/A
2026-06-23	37	$186.60	—	—	N/A

Date

Quality

Price

Value

MoS

Rating

2026-10-16

$306.24

—

N/A

2026-09-14

$278.26

—

N/A

2026-08-12

$282.00

—

N/A

2026-07-10

$233.60

—

N/A

2026-07-02

$229.09

—

N/A

2026-06-25

$202.10

—

N/A

2026-06-23

$186.60

—

N/A

Quality gate · 37/100

Moat & management

Owner-earnings inputs

History